(RTTNews) - 1ST Biotherapeutic and SK Biopharmaceuticals (326030.KS) announced an exclusive global licensing agreement and strategic equity investment partnership to advance 1ST-104, an investigational oral small-molecule candidate for Parkinson's disease.